Today: 7 February 2026
Subscribe
Browse Category

Pharmaceuticals News 20 November 2025 - 25 November 2025

NVO Stock Today: Novo Nordisk Rebounds on New Weight‑Loss Drug Data After Alzheimer’s Blow (Nov. 25, 2025)

NVO Stock Today: Novo Nordisk Rebounds on New Weight‑Loss Drug Data After Alzheimer’s Blow (Nov. 25, 2025)

Key takeaways NVO stock today: price and trading snapshot (Nov. 25, 2025) As of late‑afternoon trading on Tuesday, November 25, 2025, Novo Nordisk A/S American Depositary Receipts (ADR), ticker NVO on the NYSE, were changing hands at about $47.08, up $2.11 on the session — a gain of roughly 4.7% versus Monday’s close. Intraday, NVO has: Despite today’s rally, NVO remains down more than 50% over the past 12 months and is trading not far above its 52‑week low around $43, according to BMO Capital data referenced in a note this morning. Investing.com That combination — deep drawdown plus sharp
25 November 2025
··
Eli Lilly (LLY) Stock Today: $1 Trillion Pharma Giant Extends Rally on Bernstein Upgrade and GLP‑1 Momentum – 25 November 2025

Eli Lilly (LLY) Stock Today: $1 Trillion Pharma Giant Extends Rally on Bernstein Upgrade and GLP‑1 Momentum – 25 November 2025

INDIANAPOLIS — November 25, 2025 — Eli Lilly and Company (NYSE: LLY) continued its remarkable run on Tuesday, as the first-ever $1 trillion pharmaceutical company saw its stock climb again on the back of fresh analyst upgrades, intensifying obesity-drug momentum and ongoing institutional and retail interest. Eli Lilly stock price today (25 November 2025) Eli Lilly shares closed around $1,092.4 on Tuesday, up just over 2% from Monday’s close near $1,070. That move extends a powerful multi-week rally and keeps the stock very close to its new 52‑week and all‑time high area around $1,095. Investing.com According to recent price history
25 November 2025
·
German Stock Market Today: DAX Rebounds as Bayer Surges on Stroke‑Drug Breakthrough – 24 November 2025

German Stock Market Today: DAX Rebounds as Bayer Surges on Stroke‑Drug Breakthrough – 24 November 2025

Germany’s stock market kicked off the new week with a relief rally on Monday, 24 November 2025 (24.11.2025). The blue‑chip DAX 40 climbed around 0.7% to close just above 23,200 points, helped by a double‑digit jump in Bayer and renewed optimism about global interest‑rate cuts, even as the latest Ifo business climate index once again highlighted the fragility of Europe’s largest economy. Investing German stock market today: DAX reclaims 23,200 points By the end of Xetra trading in Frankfurt on Monday: Intraday, the DAX traded in a relatively wide range, opening near 23,280, dipping toward 23,150 at the lows and
25 November 2025
·
SRPT Stock Today, November 25, 2025: Sarepta Rises on SRP‑1003 Progress While Elevidys Risks Still Loom

SRPT Stock Today, November 25, 2025: Sarepta Rises on SRP‑1003 Progress While Elevidys Risks Still Loom

Shares of Sarepta Therapeutics (NASDAQ: SRPT) head into Tuesday’s session trying to build on a rare rally, as investors digest a positive safety update for its experimental RNA therapy SRP‑1003 and weigh it against fresh FDA warnings and trial setbacks tied to its gene therapy Elevidys. SRPT stock today at a glance As of Monday’s close (November 24, 2025), here’s where SRPT stands: In other words, Monday’s bounce was meaningful, but comes after a brutal collapse from triple‑digit levels earlier in 2025. New SRP‑1003 data: a rare bright spot for SRPT stock On Monday, Sarepta released a progress update for
25 November 2025
··
VKTX Stock Today, November 25, 2025: Can Viking Therapeutics Keep Riding the Obesity Drug Wave?

VKTX Stock Today, November 25, 2025: Can Viking Therapeutics Keep Riding the Obesity Drug Wave?

Viking Therapeutics (NASDAQ: VKTX) heads into the Tuesday, November 25, 2025 session trading in the mid‑$30s, still digesting last week’s major milestone: the company has finished enrolling patients in its pivotal Phase 3 obesity trial VANQUISH‑1 ahead of schedule and above its original target. Viking Therapeutics InvestorRoom As of yesterday’s close (Monday, November 24), VKTX changed hands at $34.65, implying a market capitalization of roughly $3.9 billion. Stock Titan Shares sit well below their 52‑week high of $56.25, but far above the 52‑week low of $18.92, underscoring how volatile the weight‑loss drug trade has become. Investing.com+1 With Phase 3 trials
25 November 2025
··
MRK Stock Today: Merck Jumps on Wells Fargo Upgrade and Keytruda Momentum (November 24, 2025)

MRK Stock Today: Merck Jumps on Wells Fargo Upgrade and Keytruda Momentum (November 24, 2025)

Merck & Co., Inc. (NYSE: MRK) is in rally mode on Monday, November 24, 2025. By early afternoon, MRK stock is trading around $101–$102 per share, up roughly 3.5–3.8% on the day, near its highest levels of 2025 and within a few percent of its 52‑week high. StockAnalysis The move comes as Wells Fargo upgraded Merck to “Overweight” from “Equal Weight” and lifted its price target to $125, alongside fresh FDA approvals and pipeline updates that strengthen the company’s story beyond flagship cancer drug Keytruda. Merck.com MRK stock today: price action and key stats As of early afternoon trading on
24 November 2025
·
BMY Stock Soars on Factor XIa Catalyst and Hematology Investor Event (Nov. 24, 2025)

BMY Stock Soars on Factor XIa Catalyst and Hematology Investor Event (Nov. 24, 2025)

Published: November 24, 2025Ticker: Bristol Myers Squibb Company (NYSE: BMY) Key takeaways This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. BMY stock today: a 4% move that stands out Bristol Myers Squibb shares climbed sharply on Monday, with BMY changing hands around $48.24, up roughly $1.99 from Friday’s close near $46.25—a gain of about 4.3% on the day. Intraday, the stock traded between roughly $46.39 and $48.63, on volume in the low‑ to mid‑teens of millions of shares—broadly in line with recent average daily trading activity,
24 November 2025
Eli Lilly Hits $1 Trillion: Weight‑Loss Drugs Turn a 150‑Year‑Old Pharma Into a Tech‑Sized Giant

Eli Lilly Hits $1 Trillion: Weight‑Loss Drugs Turn a 150‑Year‑Old Pharma Into a Tech‑Sized Giant

Published November 24, 2025 Eli Lilly has done something no other health‑care company has ever achieved: it has joined the $1 trillion market‑capitalization club, a group previously dominated almost entirely by technology giants like Apple, Microsoft and Nvidia. After briefly crossing the 13‑figure threshold on Friday, Lilly’s stock was still trading around $1,058 per share on Monday, valuing the Indianapolis‑based drugmaker at roughly $1.0 trillion and cementing its status as the first pharmaceutical company in that elite group. Reuters+1 The catalyst is clear: a once‑in‑a‑generation boom in highly effective weight‑loss and diabetes drugs such as Mounjaro and Zepbound, built on
24 November 2025
··
Novo Nordisk Stock Plunges After Alzheimer’s Drug Failure: NVO Price, News and Outlook Today (24 November 2025)

Novo Nordisk Stock Plunges After Alzheimer’s Drug Failure: NVO Price, News and Outlook Today (24 November 2025)

Danish pharma giant Novo Nordisk is under intense pressure today after its high‑profile Alzheimer’s trials for semaglutide failed, sending the stock to multi‑year lows and capping a brutal year for NVO shareholders. Novo Nordisk stock today: how far has NVO fallen? Novo Nordisk’s Alzheimer’s setback is hitting the share price hard on Monday, 24 November 2025: Despite the sell‑off, Novo Nordisk still carries a market capitalisation in the $210–215 billion range, according to multiple data providers — down sharply from its 2024 peak, but still firmly in “mega‑cap” territory. Companies Market Cap+2MacroTrends+2 For investors, today’s move is less about short‑term
24 November 2025
·
Recursion Pharmaceuticals (RXRX) Stock Today: ‘Hold’ Rating, New Institutional Buying and AI Drug Discovery Hype — November 23, 2025

Recursion Pharmaceuticals (RXRX) Stock Today: ‘Hold’ Rating, New Institutional Buying and AI Drug Discovery Hype — November 23, 2025

Snapshot: Where RXRX Stands Going Into the New Week Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) closed Friday, November 21, 2025, at $4.17, up 8.31% on the day after bouncing off the low‑$3 range earlier in the week. Volume was heavy at roughly 33 million shares, and the stock now trades near the bottom of its 52‑week range of $3.79–$12.36.StockInvest+1 The company’s market capitalization sits a little above $2.1 billion, and technically RXRX remains below both its 50‑day and 200‑day moving averages (around $5.2 and $5.1 respectively), underscoring how deep the recent pullback has been despite Friday’s sharp bounce.MarketBeat Because U.S. markets
24 November 2025
···
Tonix Pharmaceuticals Stock on November 23, 2025: Tonmya Launch, Bigger Buyback, and a $400M ATM Shape the TNXP Trade

Tonix Pharmaceuticals Stock on November 23, 2025: Tonmya Launch, Bigger Buyback, and a $400M ATM Shape the TNXP Trade

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) heads into Sunday, November 23, 2025, with its first commercial fibromyalgia drug now on pharmacy shelves, a beefed‑up share repurchase program, and a sharply expanded at‑the‑market (ATM) equity facility. Together, those moves are redefining the risk‑reward profile of this small‑cap biotech just as investors focus on how quickly new product Tonmya can ramp. Tonix Pharmaceuticals Holding Corp.+2Investing.com+2 TNXP stock today: price, performance and valuation U.S. markets are closed today, but the latest full trading session for Tonix Pharmaceuticals stock (TNXP) was Friday, November 21, 2025: On the fundamentals side, MarketBeat data paint a classic
23 November 2025
··
Pfizer (PFE) on 23 Nov 2025: Metsera Deal, Cancer Win and a 7% Dividend

Pfizer (PFE) on 23 Nov 2025: Metsera Deal, Cancer Win and a 7% Dividend

Published: November 23, 2025 Pfizer Inc. (NYSE: PFE) heads into the new week with its share price stuck around the mid‑$20s, a near‑7% dividend yield, and a flurry of fresh headlines that could shape the stock’s next move. Over the past few days the pharma giant has closed a multibillion‑dollar obesity acquisition, secured a major new U.S. cancer approval, sold $6 billion in new bonds and agreed to a $41.5 million legal settlement in Texas – while new analysis published today highlights both its long‑term potential and its risks. Reuters+3Pfizer+3Pfizer+3 Below is a roundup of the latest news and analysis
23 November 2025
··
Pfizer Stock Today, November 22, 2025: 7% Dividend, $6 Billion Bond Sale and New Health Scare Put PFE Back in Focus

Pfizer Stock Today, November 22, 2025: 7% Dividend, $6 Billion Bond Sale and New Health Scare Put PFE Back in Focus

Pfizer stock heads into the weekend trading just above $25, with investors digesting a busy week of news: a strong Q3 earnings beat, a fresh FDA cancer-drug approval, completion of a multi‑billion‑dollar obesity deal, a new $6 billion bond issue – and even a headline‑grabbing bird flu case that once again reminds markets of Pfizer’s role in vaccines and antivirals. Benzinga+3Business Wire+3Pfizer+3 Pfizer stock price today: where PFE stands on November 22, 2025 U.S. markets are closed today (Saturday), so the latest full trading session for Pfizer Inc. (NYSE: PFE) is Friday, November 21, 2025: Data providers like IndMoney and
23 November 2025
···
Merck (MRK) Stock Today: Mini‑Tender Warning, Dividend Hike and Drug Wins – 22 November 2025

Merck (MRK) Stock Today: Mini‑Tender Warning, Dividend Hike and Drug Wins – 22 November 2025

Merck & Co., Inc. (NYSE: MRK) is firmly in the spotlight this weekend as the U.S. pharma giant juggles shareholder protection, a higher dividend, and fresh regulatory wins — all while its share price trades near the upper end of its 12‑month range. Note: This article refers to Merck & Co., Inc., the U.S. company based in Rahway, New Jersey (ticker MRK on the NYSE), not German Merck KGaA (Xetra: MRK). Key takeaways for 22 November 2025 Merck (MRK) stock snapshot As of the latest trading data, Merck shares are trading around $97.76, up about 2.9% on the day, after
22 November 2025
··
Novo Nordisk Stock on 21 November 2025: NVO Slips as Denmark Grants Eye-Damage Payouts and GLP‑1 Price War Escalates

Novo Nordisk Stock on 21 November 2025: NVO Slips as Denmark Grants Eye-Damage Payouts and GLP‑1 Price War Escalates

Novo Nordisk stock is back in the spotlight today, 21 November 2025, as a cluster of breaking headlines hits the world’s most closely watched weight‑loss drug maker. As of late morning in New York, Novo Nordisk’s U.S. ADR (NYSE: NVO) is trading around $47.07, down roughly 1.1% on the day, giving the company a market value close to $213 billion. In Copenhagen, Novo Nordisk’s B‑shares finished the session around DKK 305, down nearly 3% and extending a steep slide that has left the stock down about 45% year‑to‑date. Investing.com+1 Today’s trading comes against a flurry of fresh news: Below is
21 November 2025
···
Pfizer Stock Today (PFE): mRNA Flu Breakthrough, $6B Metsera Bonds and a 7% Dividend – Nov. 21, 2025

Pfizer Stock Today (PFE): mRNA Flu Breakthrough, $6B Metsera Bonds and a 7% Dividend – Nov. 21, 2025

Pfizer’s share price is back in the spotlight on Friday, November 21, 2025, as investors digest strong Phase 3 flu-vaccine data, a $6 billion bond sale to fund its obesity-drug deal, and ongoing debate around the company’s roughly 7% dividend yield. Pfizer stock price on November 21, 2025 Pfizer (NYSE: PFE) staged a solid rebound in Friday’s regular session: For context, Pfizer’s shares are still down about 8% year-to-date, even as the broader large-cap pharma peer group has gained more than 15%, according to new Zacks analysis. Nasdaq That combination — a beaten-down share price, a high yield and fresh
21 November 2025
···
Telomir Pharmaceuticals (TELO) Unveils Leukemia Breakthrough and Board Change – Full Investor Update for November 21, 2025

Telomir Pharmaceuticals (TELO) Unveils Leukemia Breakthrough and Board Change – Full Investor Update for November 21, 2025

Telomir Pharmaceuticals (NASDAQ: TELO) shares react to new preclinical leukemia data and a director resignation on November 21, 2025. Here’s what today’s Telomir-1 news means for TELO stock and investors. What happened to Telomir Pharmaceuticals (TELO) today? On Friday, November 21, 2025, Telomir Pharmaceuticals, Inc. (NASDAQ: TELO), a Miami‑based preclinical biotech focused on small‑molecule therapies for cancer, aging and age‑related disease, released a new press release highlighting fresh in‑vitro data in human leukemia cells. Finanznachrichten In parallel, investors digested a separate corporate governance update: the company disclosed that board member Dr. Craig Eagle has stepped down, effective November 14, 2025,
21 November 2025
··
Pfizer Stock Today, November 20, 2025: Price Slide, Dividend Debate, Flu Shot Win and Texas Settlement

Pfizer Stock Today, November 20, 2025: Price Slide, Dividend Debate, Flu Shot Win and Texas Settlement

Pfizer stock (NYSE: PFE) spent most of Thursday in the red as investors weighed a near‑7% dividend yield against fresh legal headlines, new R&D wins and ongoing questions about the company’s post‑COVID growth story. As of late U.S. trading on November 20, 2025, Pfizer shares were changing hands around $24.45, down roughly 1.7% on the day, with heavy volume of more than 44 million shares. Below is a deep dive into what’s moving PFE today—and what it could mean for the stock in the weeks ahead. Pfizer Share Price on November 20, 2025 A German market recap noted that despite
20 November 2025
··
Moderna (MRNA) Sets 3‑Year mRNA Growth Plan After $1.5 Billion Loan and $140 Million U.S. Expansion – November 20, 2025

Moderna (MRNA) Sets 3‑Year mRNA Growth Plan After $1.5 Billion Loan and $140 Million U.S. Expansion – November 20, 2025

Moderna (MRNA) secured a $1.5 billion Ares loan, outlined a three‑year strategy targeting up to 10% revenue growth in 2026, and confirmed a $140 million U.S. manufacturing expansion as it races toward cash breakeven by 2028. Moderna’s pivotal day: liquidity boost, strategy reset and manufacturing push Moderna, Inc., the mRNA‑vaccine pioneer behind Spikevax®, is back in the spotlight today after unveiling a trio of significant updates on November 20, 2025: The moves come as Moderna tries to navigate a steep post‑pandemic revenue reset, heavy R&D spending and investor skepticism about how quickly its broad mRNA pipeline can translate into sustainable
20 November 2025
··
Psyence BioMed (NASDAQ: PBM) Jumps as It Secures Pharmaceutical‑Grade Ibogaine Supply for Global Clinical Trials – 20 November 2025

Psyence BioMed (NASDAQ: PBM) Jumps as It Secures Pharmaceutical‑Grade Ibogaine Supply for Global Clinical Trials – 20 November 2025

Psyence Biomedical Ltd. (NASDAQ: PBM) (“Psyence BioMed”) is back in the spotlight today after announcing a “major breakthrough” in its ibogaine supply chain and emerging as one of the more active healthcare micro‑caps in pre‑market trading. The Nasdaq‑listed psychedelic biotech disclosed that it has secured a sustainable, pharmaceutical‑grade ibogaine supply through its strategic partner PsyLabs, including an initial shipment of 50 kg of high‑potency iboga bark that is now being processed into ibogaine HCl and full‑spectrum Total Alkaloid Extracts for global clinical and therapeutic markets. GlobeNewswire+1 At the same time, Psyence BioMed’s stock was flagged by Benzinga among Thursday’s top
20 November 2025
··
1 … 26 27 28 29 30 … 34

Stock Market Today

Micron stock jumps into the weekend: UBS lifts target to $450 as Nvidia HBM4 doubts surface

7 February 2026
New York, Feb 7, 2026, 11:09 (EST) — Market closed. Micron Technology, Inc. shares finished Friday up 3.08% at $394.69, after trading between $372.87 and $396.65. With U.S. markets shut for the weekend, the stock heads into Monday with investors split between a bullish pricing story and a fresh jab at Micron’s position in AI memory. (Investing.com) Why it matters now: memory has turned into a frontline trade in the AI build-out. Big tech firms including Amazon, Alphabet, Microsoft and Meta are expected to spend more than $630 billion this year as they push deeper into artificial intelligence, putting suppliers
Costco stock price retakes $1,000 — what traders are watching before Monday

Costco stock price retakes $1,000 — what traders are watching before Monday

7 February 2026
Costco closed Friday up 1.2% at $1,001.16, regaining the $1,000 level as about 2.36 million shares changed hands. January net sales rose 9.3% to $21.33 billion, with comparable sales up 7.1% and online sales surging 34.4%. Wells Fargo raised its price target to $950, maintaining a neutral rating. The next earnings call is set for March 5.
Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

7 February 2026
Johnson & Johnson shares rose 0.9% to $239.99 Friday after a New Jersey appeals court disqualified Beasley Allen from state talc cases, citing improper coordination with a former J&J attorney. The ruling affects about 3,600 state lawsuits, while a related federal motion is pending. J&J also reported early 12-month pilot data for its investigational AFib device at a cardiology meeting.
Go toTop